Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1199 - 1208 |
| Number of pages | 10 |
| Journal | AIDS |
| Volume | 27 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2013 |
Cite this
}
Persistent immune activation in chronic HIV infection: do any interventions work? / Rajasuriar, Reena; Khoury, Gabriela; Kamarulzaman, Adeeba Binti; French, Martyn A; Cameron, Paul Urquhart; Lewin, Sharon R.
In: AIDS, Vol. 27, No. 8, 2013, p. 1199 - 1208.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Persistent immune activation in chronic HIV infection: do any interventions work?
AU - Rajasuriar, Reena
AU - Khoury, Gabriela
AU - Kamarulzaman, Adeeba Binti
AU - French, Martyn A
AU - Cameron, Paul Urquhart
AU - Lewin, Sharon R
PY - 2013
Y1 - 2013
N2 - Persistent immune activation (IA) is a hallmark of chronic HIV infection. IA has been associated with poor CD4 T-cell recovery, non-AIDS defining illnesses and mortality during combination antiretroviral therapy (cART). Measures of chronic immune activation, namely T-cell activation and more recently monocyte activation and plasma inflammatory and thrombotic biomarkers, have all been shown to remain elevated despite years of suppressive cART. Here we review recent clinical trials and therapeutic approaches targeted to reduce persistent IA in HIV patients and discuss the impact of each of these approaches on clinically relevant end-points.
AB - Persistent immune activation (IA) is a hallmark of chronic HIV infection. IA has been associated with poor CD4 T-cell recovery, non-AIDS defining illnesses and mortality during combination antiretroviral therapy (cART). Measures of chronic immune activation, namely T-cell activation and more recently monocyte activation and plasma inflammatory and thrombotic biomarkers, have all been shown to remain elevated despite years of suppressive cART. Here we review recent clinical trials and therapeutic approaches targeted to reduce persistent IA in HIV patients and discuss the impact of each of these approaches on clinically relevant end-points.
UR - http://www.natap.org/2013/HIV/Persistent_immune_activation_in_chronic_HIV.98703.pdf
U2 - 10.1097/QAD.0b013e32835ecb8b
DO - 10.1097/QAD.0b013e32835ecb8b
M3 - Article
VL - 27
SP - 1199
EP - 1208
JO - AIDS
JF - AIDS
SN - 0269-9370
IS - 8
ER -